Diabetic Gastroparesis

MAC is currently running a trial to test a new treatment for diabetic gastroparesis. Gastroparesis is where the stomach muscles fail to empty the stomach normally and diabetes is the most common cause of the condition. Diabetic gastroparesis is a chronic condition that requires prolonged treatment and core signs and symptoms include nausea, abdominal pain, bloating and vomiting.

The trial medication is called Relamorelin and will be administered via a pen injector for injection under the skin, twice daily for 12 weeks of the 16-week trial period. Relamorelin is being developed to address the existing unmet need for an effective, safe and tolerable treatment and the trial will determine if it can help reduce vomiting episodes and associated symptoms of the condition.​

Criteria:

Key Inclusion Criteria

• Diagnosis of Type 1 or Type 2 Diabetes for at least 5 years, with controlled and stable blood glucose levels within the past 6 months
• Symptoms of diabetic gastroparesis for at least the past 3 months, including; nausea, abdominal pain, bloating, vomiting and feeling full after only a few bites

Key Exclusion Criteria

• Currently taking opioids or expecting to use opioids during the study e.g. codeine, morphine, tramadol
• Symptomatic Irritable Bowel Syndrome
• History of intestinal malabsorption (including celiac disease even if well-controlled on a gluten free diet) or history of non-celiac gluten sensitivity

​

Other eligibility criteria will apply. Please contact MAC for more information.

Any other information

Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician.